

Table 1. Summary of Natural History Study Mechanistic Samples for Participants over Baseline & Follow-up (Incomplete Collection/Visit Hx Permissible*). Subjects that Develop T1D at some point during P2 or P3 are Excluded.
 P2 (n=1170); P3:6m (n=541); P3:12m (n=346); P3:18m (n=242) P3:24m (n=143); P3:30m (n=74); P3:36m (n=38)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing	Total No. Subjects Submitting Sample (%)
Baseline	DNA	314 (45.7)	120 (17.5)	235 (34.2)	18 (2.6)	687 (58.7)
	HLA	549 (48.0)	185 (16.2)	366 (32.0)	43 (3.8)	1143 (97.7)
	RNA	252 (47.3)	93 (17.4)	173 (32.5)	15 (2.8)	533 (45.6)
	PLASMA	245 (47.6)	88 (17.1)	168 (32.6)	14 (2.7)	515 (44.0)
	SERUM	246 (47.3)	90 (17.3)	169 (32.5)	15 (2.9)	520 (44.4)
	PBMC	244 (47.3)	91 (17.6)	167 (32.4)	14 (2.7)	516 (44.1)
Follow-up (6m)	RNA	138 (50.0)	44 (15.9)	88 (31.9)	6 (2.2)	276 (51.0)
	PLASMA	133 (49.3)	44 (16.3)	87 (32.2)	6 (2.2)	270 (49.9)
	SERUM	136 (49.8)	44 (16.1)	87 (31.9)	6 (2.2)	273 (50.5)
	PBMC	133 (49.3)	44 (16.3)	87 (32.2)	6 (2.2)	270 (49.9)
Follow-up (12m)	RNA	86 (43.4)	37 (18.7)	71 (35.9)	4 (2.0)	198 (57.2)
	PLASMA	84 (43.3)	37 (19.1)	69 (35.6)	4 (2.1)	194 (56.1)
	SERUM	85 (43.8)	37 (19.1)	68 (35.1)	4 (2.1)	194 (56.1)
	PBMC	86 (43.7)	37 (18.8)	70 (35.5)	4 (2.0)	197 (56.9)
Follow-up (18m)	RNA	73 (45.3)	25 (15.5)	59 (36.6)	4 (2.5)	161 (66.5)
	PLASMA	73 (46.2)	25 (15.8)	56 (35.4)	4 (2.5)	158 (65.3)
	SERUM	72 (45.6)	25 (15.8)	57 (36.1)	4 (2.5)	158 (65.3)
	PBMC	73 (45.6)	25 (15.6)	58 (36.3)	4 (2.5)	160 (66.1)
Follow-up (24m)	RNA	44 (40.7)	19 (17.6)	43 (39.8)	2 (1.9)	108 (75.5)
	PLASMA	44 (40.7)	19 (17.6)	43 (39.8)	2 (1.9)	108 (75.5)
	SERUM	44 (40.7)	19 (17.6)	43 (39.8)	2 (1.9)	108 (75.5)
	PBMC	44 (40.7)	19 (17.6)	43 (39.8)	2 (1.9)	108 (75.5)
Follow-up (30m)	RNA	25 (39.1)	12 (18.8)	25 (39.1)	2 (3.1)	64 (86.5)
	PLASMA	26 (40.0)	12 (18.5)	25 (38.5)	2 (3.1)	65 (87.8)
	SERUM	26 (40.0)	12 (18.5)	25 (38.5)	2 (3.1)	65 (87.8)
	PBMC	26 (40.0)	12 (18.5)	25 (38.5)	2 (3.1)	65 (87.8)
Follow-up (36m)	RNA	16 (53.3)	5 (16.7)	8 (26.7)	1 (3.3)	30 (78.9)
	PLASMA	16 (53.3)	5 (16.7)	8 (26.7)	1 (3.3)	30 (78.9)
	SERUM	16 (53.3)	5 (16.7)	8 (26.7)	1 (3.3)	30 (78.9)
	PBMC	16 (53.3)	5 (16.7)	8 (26.7)	1 (3.3)	30 (78.9)

* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, although a subject doesn't necessarily need to have completed all prior P3 visits for inclusion in their latest P3 visit.
 ** All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.
 T:\Protocols\Natural History-Mahon\Mechanistic\MechanisticSamples_Programs&Reports\Current\20080901_Tables